Serum total homocysteine concentration does not predict outcome in renal transplant recipients

Clinical Transplantation

Volumn 12, Issue 6, 1998, Pages 563-568

  Dimény, Emöke ^a   Hultberg, Björn ^b   Wahlberg, Jan ^c   Fellström, Bengt ^c   Arnadottir, Margret ^d  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Graft survival; Homocysteine; Renal transplantation

Indexed keywords

CREATININE; HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BIOPSY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; BIOPSY, NEEDLE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HOMOCYSTEINE; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0031722632     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. THE CANADIAN MULTICENTRE TRANSPLANT STUDY GROUP. A randomized trial of cyclosporine in cadaveric renal transplantation. New Engl J Med 1986: 314: 1219.
2. FOSTER MC, DENNIS MJS. Chronic renal graft rejection. In: PAUL LC, SOLEZ K, eds. Organ Transplantation: Long-term Results. New York: Marcel Dekker, 1992: 153.
3. PAUL LC. Chronic renal transplant loss. Kidney Int 1995: 47: 1491.
4. LINDHOLM A. ALBRECTSEN D. FRÖDIN L, TUFVESSON G, PERSSON NH. LUNDGREN G. Ischemic heart disease - a major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995: 60: 451.
5. MA KW, GREENE EL, RAJI L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992: 14: 505.
6. MARKELL MS. ARMENTI V, DANOVITCH G, SUMRANI N. Hyperlipidemia and glucose tolerance in the post-renal transplant patient. J Am Soc Nephrol 1994: 4: 37.
7. KASISKE BL. Atherosclerosis in organ transplant recipients. In: PAUL LC, SOLEZ K, eds. Organ Transplantation: Long-term Results. New York: Marcel Dekker, 1992: 283.
8. DIMENY E, TUFVESSON G, LITHELL H, LARSSON E, SIEGBAHN A, FELLSTRÖM B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993: 23: 72.
9. DIMÉNY E, WAHLBERG J, LITHELL H, FELLSTRÖM B. Hyperlipidaemia in renal transplantation - risk factor for long-term graft outcome. Eur J Clin Invest 1995: 25: 574.
10. DIMÉNY E. Metabolic factors and outcome of organ transplantation. Scand J Urol Nephrol 1994: suppl. 159: 1.
11. ISONIEMI H, NURMINEN M, TIKKANEN MJ, VON-WILLEBRAND E, KROGERUS L, AHONEN J, EKLUND B, HÖKKERSTEDT K, SALMELA K, HAYRY P. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994: 57: 69.
12. MASSY ZA, GUIJARRO C, WIEDERKEHR MR, MA JZ, KASISKE BL. Chronic renal allograft rejection: immunologic and nonmmunologic risk factors. Kidney Int 1996: 49: 518.
13. BUMGARDNER GL, WILSON GA, TSO PL, HENRY ML, ELKHAMMAS EA, DAVIES EA, QIU W, FERGUSON RM. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 1995: 60: 1418.
14. KATZNELSON S, WILKINSON AH, KOBASHIGAWA JA, WANG XM, CHIA D, OZAWA M, ZHONG HP, HIRATA M, COHEN AH, TERASAKI PI, DANOVITCH GM. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996: 61: 1469.
15. STAMPFER MJ, MALINOW MR, WILLETT WC, NEWCOMER LM, UPSON B, ULLMAN D, TISHLER PV, HENNEKENS CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992: 268: 877.
16. VERHOEF P, HENNEKENS CH, MALINOW R, KOK FJ, WILLETT WC, STAMPFER MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994: 25: 1924.
17. ARNESEN E, REFSUM H, BÖNA KH, UELAND PM. FöRDE OH, NORDREHAUG JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995: 24: 704.
18. PERRY IJ, REFSUM H, MORRIS RW, EBRAHIM SB, UELAND PM, SHAPER AG. Prospective study of serum homocysteine concentrations and risk of stroke in middle-aged British men. Lancet 1995: 346: 1398.
19. UELAND PM, REFSUM H, BRATTSTRÖM L. Plasma homocysteine and cardiovascular disease. In: FRANCIS JR RB, ed. Atherosclerotic, Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Marcel Dekker. 1992: 183.
20. BOUSHEY CJ. BERESFORD SAA, OMENN GS, MOTULSKY AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1995: 274: 1049.
21. NYGÅRD O, NORDREHAUG JE, REFSUM H. UELAND PM, FARSTAD M, VOLLSET SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. New Engl J Med 1997: 337: 230.
22. WILCKEN DEL, GUPTA VJ, BETTS AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981: 61: 743.
23. MASSY ZA, CHADEFAUX-VEKEMANS B, CHEVALIER A, BADER CA, DRUEKE TB, LEGENDRE C, LACOUR B, KAMOUN P, KREIS H. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994: 9: 1103.
24. ARNADOTTIR M, HULTBERG B, VLADOV V, NILSSONEHLE P, THYSELL H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996: 61: 509.
25. RAINE AEG, MARGREITER R, BRUNNER FP, EHRICH JHH, GEERLINGS W, LANDAIS P, LOIRAT C, MALLICK NP, SELWOOD NH, TUFVESSON G, VALDERRABANO F. Report on management of renal failure in Europe. XXII, 1991. Nephrol Dial Transplant 1992: 7 (suppl. 2): 7.
26. LINDHOLM A, ALBRECHTSEN D, TUFVESSON G, KARLBERG I, PERSSON NH, GROTH CG. A randomized trial of cyclosporine and prednisolone versus cyclosporine, azathioprine and prednisolone in primary cadaveric renal transplantation. Transplantation 1992: 54: 624.
27. UELAND PM, REFSUM H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989: 114: 473-501.
28. ANDERSSON A, ISAKSSON A, BRATTSTROM L, HULTBERG H. Determination of homocysteine and other thiols in human plasma by high performance liquid chromatography and a thiol-specific postcolumn derivatization procedure. Clin Chem 1993: 39: 1590.
29. WAHLBERG J, ANDERSSON T, BUSCH C, FELLSTRÖM B, FRODIN L, LARSSON A, LARSSON E, LINDGREN PG, TUFVESSON G. The Biopty TM biopsy technique - major advantages in the monitoring of renal transplant recipients. Transplant Proc 1988: 20: 419.
30. HANÅS E, LARSSON E, FELLSTRÖM B, LINDGREN PG, ANDERSSON T, BUSCH C, FRÖDIN L, WAHLBERG J, TUFVESSON G. Safety aspects and diagnostic findings of serial renal allograft biopsies, obtained by an automatic technique with a midsize needle. Scand J Urol Nephrol 1992: 26: 413.
31. DIMÉNY E, WALLBERG J, LARSSON E, FELLSTROM B. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995: 9: 79.
32. FOEGH ML. Chronic rejection - graft arteriosclerosis. Transplant Proc 1990: 22: 119.
33. TAWAKOL A, OMLAND T, GERHARD M, Wu JT, CREAGER MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997: 95: 1119.
34. UPCHURCH GR, WELCH GN, RANDEV V, FABIAN A, KEANEY J JR, LOSCALZO J. The effect of homocysteine on endothelial nitric oxide production (abstract). FASEB 1995: 9: 876.
35. LIAO JK, SHIN WS, LEE WY, CLARK SL. Oxidized low-density lipoprotem decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995: 270: 319.
36. JAKUBOWSKI H. Metabolism of homocysteine thiolactone in human cell cultures. J Biol Chem 1997: 272: 1935.
37. SELHUB J, D'ANGELO A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thrombosis Haemostasis 1997: 78: 527.
38. ARNADOTTIR M, HULTBERG B, NILSSON-EHLE P, THYSELL H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996: 56: 41.